Fig. 1: Blood-based brain-derived tau (BD-tau) mean differences across cohorts 1 to 3, compared to A-/N- cases.
From: Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
This forest plot displays the mean elevation of blood-based BD-tau according to cerebrospinal fluid (CSF) determined amyloid (A) and neurodegeneration (N) status in the Alzheimer’s Disease (AD) continuum across cohorts 1 through 3. Point estimates are log-transformed and standardized (Z-log), expressed as standard deviations relative to A-/N- cases (represented by a gray vertical bar, normalized to mean 0 as the reference). Error bars denote 95% confidence intervals. All statistical tests were two-sided and unadjusted for multiple comparisons. For cohort 1 (Dementia Disease Initiation (DDI)), A-/N- were cognitively normal (CN, n = 157). For cohort 2 (University of Gothenburg), A-/N- were CN (A-/N-, n = 9). For cohort 3 (Biodegmar, Hospital del Mar, Barcelona memory clinic cohort), A-/N- (n = 111) were mixed CN with Subjective Cognitive Decline, Mild Cognitive Impairment (MCI) and dementia.
